C-reactive protein augments interleukin-8 secretion in human peripheral blood monocytes

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 5, 2005, Pages 690-696

  Xie, Liangqi ^a   Chang, Lina ^a   Guan, Youfei ^a   Wang, Xian ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Macrophages

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA CHEMOKINE; ARSENOSOBENZENE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CHEMOKINE; C REACTIVE PROTEIN; CATALASE; CHEMOKINE; DIMETHYL SULFOXIDE; DIPHENYLIODONIUM SALT; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER; SUPEROXIDE DISMUTASE; TROGLITAZONE; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; RISK FACTOR;

C-REACTIVE PROTEIN; CELLS, CULTURED; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-8; MONOCYTES; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 27344443420     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000183568.48389.a1     Document Type: Article

References (46)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
3. Biasucci LM, Liuzzo G, Grille RL, et al. Elevated level s of C-reactive protein at discharge in patients with unstable angina predicts recurrent instability. Circulation. 1999;99:855-860.
4. Gaspardone A, Grea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol. 1998;82:515-518.
5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
6. Ridker PM, Burug JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-773.
7. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med. 2004;14:161-165.
8. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004;36:98-118.
9. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127.
10. Apostolopoulos J, Davenport P, Tipping PG. Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol. 1996;16:1007-1012.
11. Wang N, Tabas I, Winchester R, et al. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem. 1996;271:8837-8842.
12. Xu L, Kelvin DJ, Ye GQ, et al. Modulation of 1L-8 receptor expression on purified human T lymphocytes is associated with changed chemotactic responses to IL-8. J Leukoc Biol. 1995;57:335-342.
13. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723.
14. Yue TL, Wang X, Sung CP, et al. Interleukin 8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ Res. 1994;75:1-7.
15. Pasceri V, Wu HD, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103: 2531-2534.
16. Hattori Y, Matsumura M, Kasai KK, et al. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003;58:186-195.
17. Zhou P, Thomassen MJ, Pettay J, et al. Human monocytes produce monocyte chemoattractant protein 1 (MCP-1) in response to a synthetic peptide derived from C-reactive protein. Clin Immunol Immunopathol. 1995;74:84-88.
18. Barna BP, Thomassen MJ, Zhou P, et al. Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J Leukoc BM. 1996;59:397-402.
19. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004; 109:2566-2571.
20. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol. 2004;36:405-410.
21. Lim MY, Wang H, Kapoun AM, et al. p38 inhibition attenuates the proinflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol. 2004;37:1111-1114.
22. Allen RC. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 1986;133: 449-493.
23. Masuzawa K, Miyauchi T, Takanashi M, et al. Effects of endothelin-1 eyedrops on the retina in rats. J Cardiovasc Pharmacol. 2004;44:S421-S425.
24. Rosenbcrger J, Petrovics G, Buzas B. Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-kappaB. J Neurochem. 2001;79:35-44.
25. Reddy RC, Keshamouni VG, Jaigirdar SH, et al. Deactivation of murine alveolar macrophages by peroxisome proliferators-activated receptor-gamma ligands. Am J Physiol Lung Cell Mol Physiol. 2004;286:L613-L619.
26. Fisher B, von Knethen A, Brune B. Dualism of oxidized lipoproteins in provoking and attenuating the oxidative burst in macrophages: role of peroxisome proliferator-activated receptor-γ. J Immunol. 2002;168:2828-2834.
27. Dlerive P, Gervois P, Fruchart JC, et al. Induction of IkB-α expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferators-activated receptor-α activators. J Biol Chem. 2000;275: 36703-36707.
28. Delerive P, Bosscher KD, Besnard S, et al. Peroxisome proliferators-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NK-kB and AP-1. J Biol Chem. 1999;274:32048-32054.
29. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4: 361-368.
30. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med. 2004;14:161-165.
31. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004;36:98-118.
32. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassay for C-reactive protein. Clin Chim Acta. 1981;117:13-23.
33. Irani K. Oxidant signaling in vascular cell growth, death, and survival. Circ Res. 2000;87:179-183.
34. Zeng X, Dai J, Daniels G, et al. Homocycteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res. 2003;93:311-320.
35. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol. 2003;23:1398-1404.
36. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
37. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000;67:495-500.
38. Ratnam S, Mookerjea S. The regulation of Superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology. 1998;94:560-568.
39. Barnes PJ, Karin M. NF-κB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med. 1997;336:1067-1071.
40. Schreck R, Albermann K, Baeuerle PA. Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radic Res Commun. 1992;17:221-237.
41. Yoshizumi M, Tsuchiya K, Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J Med Invest. 2001;48:11-24.
42. Koch A, Giembycz M, Stirling RG, et al. Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J. 2004;23:805-812.
43. Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol. 2002;3: 69-75.
44. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads to lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455-480.
45. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312.
46. Khreiss T, Jozsef L, Potempa LA, et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109:2016-2022.